Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT (DOTAGLI)
The purpose of this study is to characterize tumour uptake of somatostatin analog 68Ga-DOTATOC in patients with either primary or recurrent malignant glioma. The investigators hypothesis is that some primary and recurrent malignant gliomas overexpress SST2 receptor which can be imaged with 68Ga-DOTATOC PET/CT. The investigators also hypothesize that tumor uptake of 68Ga-DOTATOC correlates with immunohistochemically determined SST2 receptor status of the tumor specimen.
|Study Design:||Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
|Official Title:||PET/CT Imaging of Malignant Glioma With Somatostatin Analog 68Ga-DOTATOC|
- Malignant glioma uptake of 68Ga-DOTATOC [ Time Frame: within 90 minutes post-injection ] [ Designated as safety issue: No ]PET/CT imaging of the brain starts immediately after the intravenous bolus injection of 68Ga-DOTATOC. Dynamic PET/CT imaging is done over 60-min. A late 90-min scan will be obtained for selected patients. PET studies are analyzed by determining the Standardized Uptake Values (SUV) of the tumor using regions of interest (ROI) drawn both manually and automatically on the tumor.
- Immunohistochemical SST2 receptor status of the tumor specimen [ Time Frame: After glioma surgery within 4 weeks of PET/CT imaging ] [ Designated as safety issue: No ]
|Study Start Date:||October 2011|
|Study Completion Date:||December 2013|
|Primary Completion Date:||December 2013 (Final data collection date for primary outcome measure)|
120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01460706
|Turku PET Centre, Turku University Hospital|
|Turku, Finland, FI-21100|
|Principal Investigator:||Heikki RI Minn, M.D., Ph.D.||Turku University Hospital|